



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/993,469	11/14/2001	Avi J. Ashkenazi	P2730PIC5	3281
35489	7590	03/25/2004	EXAMINER	
HELLER EHRMAN WHITE & MCAULIFFE LLP			KAUFMAN, CLAIRE M	
275 MIDDLEFIELD ROAD			ART UNIT	
MENLO PARK, CO 94025-3506			PAPER NUMBER	

1646

DATE MAILED: 03/25/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/993,469

Applicant(s)

ASHKENAZI ET AL.

Examiner

Claire M. Kaufman

Art Unit

1646

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 14 November 2001.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 119-131 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 119-131 is/are rejected.
- 7) ☒ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 14 November 2001 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- ☒ Notice of References Cited (PTO-892)
- ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date 5/28/02.
- ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____
- ☐ Notice of Informal Patent Application (PTO-152)
- ☒ Other: sequence comparison.

DETAILED ACTION

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 119-124, 127, 128, 130 and 131 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for the protein of SEQ ID NO:52 or the protein of SEQ ID NO:52 except lacking its associated signal sequence, does not reasonably provide enablement for other protein. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.

The factors considered when determining if the disclosure satisfies the enablement requirement and whether any necessary experimentation is undue include, but are not limited to: 1) nature of the invention, 2) state of the prior art, 3) relative skill of those in the art, 4) level of predictability in the art, 5) existence of working examples, 6) breadth of claims, 7) amount of direction or guidance by the inventor, and 8) quantity of experimentation needed to make or use the invention. *In re Wands*, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988).

The protein of SEQ ID NO:52 is called PRO1282 which is 673 amino acids long, with a putative signal sequence from residue 1-23, transmembrane domain from 579-599, leucine zipper region from 197-269 and EGF-like domain beginning at 430 (p. 414, lines 13-16). The encoded protein tested positive in the Chondrocyte Redifferentiation Assay (#110, p. 530) and the encoding nucleic acid was shown to have a ΔC_t slightly greater than 1 for 2/17 colon tumors ($\Delta C_t = 1.15$ and 1.07) tested and none of the 12 lung tumors tested (p. 554).

The claims are broad, including polypeptides 80% identical to only the extracellular domain of SEQ ID NO:52. There is no functional limitation associated with the protein in the claims. Aside from the positive outcome in the chondrocyte redifferentiation assay there is no function associated with PRO1282, and its specific role in the redifferentiation is not disclosed.

Art Unit: 1646

Blast results submitted by Applicant and other sequence comparison shows that PRO1282 is most structurally related to slit and riken proteins, however, the function of these proteins is unclear. Itoh et al. cloned human homologues of *Drosophila* slit and suggests a possible role for mammalian slit in formation and maintenance of the nervous and endocrine system based on its role in *Drosophila* and its tissue expression in human and rat (p. 185, 2 paragraphs beginning the last paragraph of col. 1). It is also noted that *Drosophila* slit is not expressed in neuronal cells, but rat slit-1 and human slit-1, -2 and -3 are (last 2 sentences of last paragraph in col. 1, p. 185). The prior art does not provide sufficient information to allow the skilled artisan to use PRO1282 without significant further research.

While the nucleic acid showed slight amplification in 2 tumor cells lines compared to normal tissue, this does not support a diagnostic use of the nucleic acid for detection of cancerous tissue. There are several reasons for this. Elevated copy number in 2/17 colon cancers does not provide the skilled artisan with a reasonable expectation that PRO1218 DNA copy number can serve as a marker for colon cancer since expression was in such a small minority of the tumors tested. Further, Lanza et al. (*Cancer*, 82:49, 1998) showed that out of 191 colon carcinomas tested, 144 (75.4%) had aneuploid DNA (p. 51, col. 2, third full paragraph). That means an increased copy number for PRO1218 in the colon tumors tested was less like due to an increase unique to PRO1282 DNA, but rather due to a more general phenomenon of aneuploidy of the DNA in those colon cancer cells. Another study of aneuploidy in colon cancers showed that in some individuals with colon cancer, aneuploidy was also found in morphologically normal colon tissue (Fleischhacker et al., *Modern Path.*, 8:360, 1995; *e.g.*, p. 360, col. 2). Because aneuploid DNA can be found in normal tissue, detection of increased DNA copy number does not necessary mean those cells containing the DNA are cancerous. Further, the ΔC_t 's of the PRO1282 DNA were extremely low, and the specification says on p. 548, lines 35-36, that "...the CT value of normal human DNA subtracted from test DNA was ± 1 Ct." In light of this, it is questionable whether a CT value of 1.07 or even 1.15 can be considered significant. Therefore in this instance, copy number does not support a basis for how to use the claimed nucleic acid. Even if the copy number provided a diagnostic use for the nucleic acid, which it does not, it would not provide a use for the encoded protein since there is no information or predictability about a link between copy number and encoded protein level.

Art Unit: 1646

While the PRO1282 protein (probably the mature form) lead to redifferentiation in the chondrocyte assay, the specification provides no information on what domains or characteristics of the protein were responsible for its effect on chondrocytes. It is unpredictable if the extracellular domain alone has the necessary function. Indeed, one skilled in the art would expect that signal transduction would be necessary for chondrocyte redifferentiation, and a soluble polypeptide cannot transduce a signal unless it is a soluble ligand able to bind to and activate a receptor. The structural elements identified by Applicants for PRO1282 makes it unlikely that it is normally a soluble ligand. Based on PRO1282's homology to slit discussed above, one could not have predicted a reasonable expectation of successful in cause chondrocyte redifferentiation. Also, while the PRO1282 protein of SEQ ID NO:52 (with or without the signal sequence) was functional in this assay, it is, at the least, unpredictable what changes could be made to SEQ ID NO:52 while retaining its redifferentiation ability.

For these reasons which include breadth of the claims, lack of information on the relationship of structure to function of PRO1282, paucity of information in the prior art, limited working example, and lack of guidance for use provided in the specification, it would require undue experimentation to use the claimed nucleic acid commensurate in scope with the claims.

Claims 119-123, 130 and 131 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The claims are drawn to polypeptides having at least 80%, 85%, 90%, 95% or 99% sequence identity with a particular disclosed sequence. The claims do not require that the polypeptide possess any particular biological activity, nor any particular conserved structure, or other disclosed distinguishing feature. Thus, the claims are drawn to a genus of polypeptides that is defined only by sequence identity.

To provide adequate written description and evidence of possession of a claimed genus, the specification must provide sufficient distinguishing identifying characteristics of the genus. The factors to be considered include disclosure of complete or partial structure, physical and/or chemical properties, functional characteristics, structure/function correlation, methods of making

Art Unit: 1646

the claimed product, or any combination thereof. In this case, the only factor present in the claim is a partial structure in the form of a recitation of percent identity. There is not even identification of any particular portion of the structure that must be conserved. Accordingly, in the absence of sufficient recitation of distinguishing identifying characteristics, the specification does not provide adequate written description of the claimed genus. Which polypeptides of the genus comprising the required sequence are part of the invention has not been set forth.

Vas-Cath Inc. v. Mahurkar, 19USPQ2d 1111, clearly states “applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the ‘written description’ inquiry, whatever is now claimed.” (See page 1117.) The specification does not “clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed.” (See *Vas-Cath* at page 1116). As discussed above, the skilled artisan cannot envision the detailed chemical structure of the encompassed genus of polypeptides, and therefore conception is not achieved until reduction to practice has occurred, regardless of the complexity or simplicity of the method of isolation. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method of isolating it. The compound itself is required. See *Fiers v. Revel*, 25 USPQ2d 1601 at 1606 (CAFC 1993) and *Amgen Inc. v. Chugai Pharmaceutical Co. Ltd.*, 18 USPQ2d 1016.

One cannot describe what one has not conceived. See *Fiddes v. Baird*, 30 USPQ2d 1481 at 1483. In *Fiddes*, claims directed to mammalian FGF’s were found to be unpatentable due to lack of written description for that broad class. The specification provided only the bovine sequence.

Therefore, only isolated polypeptides comprising the amino acid sequence set forth in SEQ ID NO: 52 with or disclosed domains thereof, but not the full breadth of the claim meets the written description provision of 35 U.S.C. § 112, first paragraph. Applicant is reminded that *Vas-Cath* makes clear that the written description provision of 35 U.S.C. § 112 is severable from its enablement provision (see page 1115).

Art Unit: 1646

Priority

Priority application 09/380,137 and earlier filed priority applications do *not* meet the requirements of 35 U.S.C. § 112, first paragraph. Because there was no function associated with PRO1282 and the skilled artisan would not have known how to use it, the prior application also does not meet those requirements and, therefore, is unavailable under 35 U.S.C. § 120. Note that even if priority were granted to the earliest filed priority application 60/097,979, the art rejection below would remain under 35 UCS 102(e).

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 119-130 are rejected under 35 U.S.C. 102(e) as being anticipated by US 6,225,085.

US 6,225,085 teaches a LRSG (leucine-rich surface glycoprotein) of SEQ ID NO:2 which is identical to SEQ ID NO:52 of the instant application. Additionally, the coding region of the LRSG nucleic acid is identical to that of SEQ ID NO:51 (see attached SEQUENCE COMPARISON). Also disclosed is the protein without or optionally with its signal sequence or with only an extracellular domain (col. 7, lines 1-27), and chimeric proteins in which a heterologous polypeptide is fused to LRSG (e.g., col. 20, lines 1-33).

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

Art Unit: 1646

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claim 131 is rejected under 35 U.S.C. 103(a) as being unpatentable over US 6,225,085 as relied upon above and Prickett et al. (BioTechniques, 7:580, 1989).

US 6,225,085 does not teach LRSG protein attached to an epitope tag.

Prickett et al teach the FLAG sequence, an eight amino acid long sequence which can fused to a heterologous protein and identified by a commercially available monoclonal antibody that can also be used as an immuno-affinity gel reagent for mild one-step purification of the resulting fusion protein. The FLAG sequence can also be easily cleaved from the fusion protein (p. 580, col. 3, first paragraph).

It would have been obvious to the artisan of ordinary skill at the time the invention was made to produce LRSG as a FLAG-fusion protein for easy and mild purification of the recombinant protein.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Claire M. Kaufman, whose telephone number is (571)272-0873. Dr. Kaufman can generally be reached Monday, Tuesday and Thursday from 8:30AM to 2:30PM.


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler, can be reached at (571)272-0871.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is (703) 308-0196.

Art Unit: 1646

Official papers filed by fax should be directed to (703) 872-9306. NOTE: If applicant *does* submit a paper by fax, the original signed copy should be retained by the applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

Claire M. Kaufman, Ph.D.

A handwritten signature in black ink, appearing to read 'Claire M. Kaufman', with a stylized flourish at the end.

Patent Examiner, Art Unit 1646

March 17, 2004

SEQUENCE COMPARISON OF SEQ ID NO:52 WITH US 6,225,085

; Sequence 2, Application US/09063950C

; Patent No. 6225085

; GENERAL INFORMATION:

; APPLICANT: Holtzman, Douglas A.

; TITLE OF INVENTION: NOVEL LRSG PROTEIN AND NUCLEIC ACID MOLECULES AND USES

; TITLE OF INVENTION: THEREFOR

; CURRENT APPLICATION NUMBER: US/09/063,950C

; CURRENT FILING DATE: 1998-04-21

; SEQ ID NO 2

; LENGTH: 673

; TYPE: PRT

; ORGANISM: Homo sapiens

US-09-063-950-2

Query Match 100.0%; Score 3520; DB 3; Length 673;
 Best Local Similarity 100.0%; Pred. No. 5.8e-249;
 Matches 673; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	MCSRVPLLLPLLLLLLALGPGVQGCPSGCQCSQPQTVFCTARQGTTPRDPVPPDTVGLYVF	60
Db	1	MCSRVPLLLPLLLLLLALGPGVQGCPSGCQCSQPQTVFCTARQGTTPRDPVPPDTVGLYVF	60
Qy	61	ENGITMLDAGSFAGLPGLQLLDLSQNQIASLPSGVFQPLANLSNLDLTANRLHEITNETF	120
Db	61	ENGITMLDAGSFAGLPGLQLLDLSQNQIASLPSGVFQPLANLSNLDLTANRLHEITNETF	120
Qy	121	RGLRRRLERLYLGKNRIRHIQPGAFDTLDRLELKLQDNELRALPPLRLPRLLLLDLSHNS	180
Db	121	RGLRRRLERLYLGKNRIRHIQPGAFDTLDRLELKLQDNELRALPPLRLPRLLLLDLSHNS	180
Qy	181	LLALEPGILDTANVEALRLAGLGQLQQLDEGLFSRLRLNLDLDVSDNQLERVPPVIRGLRG	240
Db	181	LLALEPGILDTANVEALRLAGLGQLQQLDEGLFSRLRLNLDLDVSDNQLERVPPVIRGLRG	240
Qy	241	LTRLRLAGNTRIAQLRPEDLAGLAALQELDVSNSLQALPGDLSGLFPRLRLAAARNPF	300
Db	241	LTRLRLAGNTRIAQLRPEDLAGLAALQELDVSNSLQALPGDLSGLFPRLRLAAARNPF	300
Qy	301	NCVCPLSWFGPWVRESHVTLASPEETRCHFPKNAGRLLLELDYADFGCPATTTTATVPT	360
Db	301	NCVCPLSWFGPWVRESHVTLASPEETRCHFPKNAGRLLLELDYADFGCPATTTTATVPT	360
Qy	361	TRPVVREPTALSSSLAPTWSPTAPATEAPSPSTAPPTVGPVPQPDCCPSTCLNGGTC	420
Db	361	TRPVVREPTALSSSLAPTWSPTAPATEAPSPSTAPPTVGPVPQPDCCPSTCLNGGTC	420
Qy	421	HLGTRHHLACLCEGFTGLYCESQMGQGTRPSPTVTPRPPRSLTLGIEPVSPTSRLVGL	480
Db	421	HLGTRHHLACLCEGFTGLYCESQMGQGTRPSPTVTPRPPRSLTLGIEPVSPTSRLVGL	480
Qy	481	QRYLQGSSVQLRSLRLTYRNLSGPDKRLVTLRLPASLAEYTVTQLRPNATYSVCMPLGP	540
Db	481	QRYLQGSSVQLRSLRLTYRNLSGPDKRLVTLRLPASLAEYTVTQLRPNATYSVCMPLGP	540

Qy	541	GRVPEGEEACGEAHTPPAVHSNHAPVTQAREGNLPLLIAPALAAVLLAALAAVGAAYCVR	600
Db	541	GRVPEGEEACGEAHTPPAVHSNHAPVTQAREGNLPLLIAPALAAVLLAALAAVGAAYCVR	600
Qy	601	RGRAMAAAAQDKGQVGPAGGLELEGVKVPLEPGPKATEGGGEALPSGSECEVPLMGFPG	660
Db	601	RGRAMAAAAQDKGQVGPAGGLELEGVKVPLEPGPKATEGGGEALPSGSECEVPLMGFPG	660
Qy	661	PGLQSPLHAKPYI	673
Db	661	PGLQSPLHAKPYI	673

SEQUENCE COMPARISON OF SEQ ID NO:51 WITH US 6,225,085

```
; Sequence 1, Application US/09063950C
; Patent No. 6225085
; GENERAL INFORMATION:
; APPLICANT: Holtzman, Douglas A.
; TITLE OF INVENTION: NOVEL LRSG PROTEIN AND NUCLEIC ACID MOLECULES AND USES
; TITLE OF INVENTION: THEREFOR
; FILE REFERENCE: MEI-019
; CURRENT APPLICATION NUMBER: US/09/063,950C
; CURRENT FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
; LENGTH: 2852
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (160)..(2178)
US-09-063-950-1
```

```
Query Match          99.5%; Score 2754.4; DB 3; Length 2852;
Best Local Similarity 99.9%; Pred. No. 0;
Matches 2767; Conservative 0; Mismatches 1; Indels 2; Gaps 1;
```

```
Qy=NO:51   1 ACTCGAACGCAGTTGCTTCGGGACCCAGGACCCCCTCGGGCCCCGACCCGCCAGGAAAGAC 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          41 ACTCGAACGCAGTTGCTTCGGGACCCAGGACCCCCTCGGGCCCCGACCCGCCAGGAAAGAC 100

Qy          61 TGAGGCCGCGGCTGCCCGCCCGGCTCCCTGCGCCGCGCGCCGCTCCCGGGACAGAAGA 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          101 TGAGGCCGCGGCTGCCCGCCCGGCTCCCTGCGCCGCGCGCCGCTCCCGGGACAGAAGA 160

Qy          121 TGTGCTCCAGGGTCCCTCTGCTGCTGCCGCTGCTCCTGCTACTGGCCCTGGGGCCTGGGG 180
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          161 TGTGCTCCAGGGTCCCTCTGCTGCTGCCGCTGCTCCTGCTACTGGCCCTGGGGCCTGGGG 220

Qy          181 TGCAGGGCTGCCCATCCGGCTGCCAGTGCAGCCAGCCACAGACAGTCTTCTGCACTGCCC 240
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          221 TGCAGGGCTGCCCATCCGGCTGCCAGTGCAGCCAGCCACAGACAGTCTTCTGCACTGCCC 280

Qy          241 GCCAGGGGACCACGGTGCCCCGAGACGTGCCACCCGACACGGTGGGGCTGTACGTCTTTG 300
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          281 GCCAGGGGACCACGGTGCCCCGAGACGTGCCACCCGACACGGTGGGGCTGTACGTCTTTG 340

Qy          301 AGAACGGCATCACCATGCTCGACGCAGGCAGCTTTGCCGGCCTGCCGGGCCTGCAGCTCC 360
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          341 AGAACGGCATCACCATGCTCGACGCAGGCAGCTTTGCCGGCCTGCCGGGCCTGCAGCTCC 400

Qy          361 TGGACCTGTCACAGAACCAGATCGCCAGCCTGCCAGCGGGGTCTTCCAGCCACTCGCCA 420
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          401 TGGACCTGTCACAGAACCAGATCGCCAGCCTGCCAGCGGGGTCTTCCAGCCACTCGCCA 460

Qy          421 ACCTCAGCAACCTGGACCTGACGGCCAACAGGCTGCATGAAATCACCAATGAGACCTTCC 480
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          461 ACCTCAGCAACCTGGACCTGACGGCCAACAGGCTGCATGAAATCACCAATGAGACCTTCC 520
```

Qy 481 GTGGCCTGCGGCGCCTCGAGCGCCTCTACCTGGGCAAGAACC GCATCCGCCACATCCAGC 540
 |||
 Db 521 GTGGCCTGCGGCGCCTCGAGCGCCTCTACCTGGGCAAGAACC GCATCCGCCACATCCAGC 580

Qy 541 CTGGTGCCTTCGACACGCTCGACCGCCTCCTGGAGCTCAAGCTGCAGGACAACGAGCTGC 600
 |||
 Db 581 CTGGTGCCTTCGACACGCTCGACCGCCTCCTGGAGCTCAAGCTGCAGGACAACGAGCTGC 640

Qy 601 GGGCACTGCCCCCGCTGCGCCTGCCCCGCCTGCTGCTGCTGGACCTCAGCCACAACAGCC 660
 |||
 Db 641 GGGCACTGCCCCCGCTGCGCCTGCCCCGCCTGCTGCTGCTGGACCTCAGCCACAACAGCC 700

Qy 661 TCCTGGCCCTGGAGCCCGGCATCCTGGACACTGCCAACGTGGAGGCGCTGCGGCTGGCTG 720
 |||
 Db 701 TCCTGGCCCTGGAGCCCGGCATCCTGGACACTGCCAACGTGGAGGCGCTGCGGCTGGCTG 760

Qy 721 GTCTGGGGCTGCAGCAGCTGGACGAGGGGCTCTTCAGCCGCTTGCGCAACCTCCACGACC 780
 |||
 Db 761 GTCTGGGGCTGCAGCAGCTGGACGAGGGGCTCTTCAGCCGCTTGCGCAACCTCCACGACC 820

Qy 781 TGGATGTGTCCGACAACCAGCTGGAGCGAGTGCCACCTGTGATCCGAGGCCTCCGGGGCC 840
 |||
 Db 821 TGGATGTGTCCGACAACCAGCTGGAGCGAGTGCCACCTGTGATCCGAGGCCTCCGGGGCC 880

Qy 841 TGACGCGCCTGCGGCTGGCCGGCAACACCCGCATTGCCAGCTGCGGCCCCGAGGACCTGG 900
 |||
 Db 881 TGACGCGCCTGCGGCTGGCCGGCAACACCCGCATTGCCAGCTGCGGCCCCGAGGACCTGG 940

Qy 901 CCGGCCTGGCTGCCCTGCAGGAGCTGGATGTGAGCAACCTAAGCCTGCAGGCCCTGCCTG 960
 |||
 Db 941 CCGGCCTGGCTGCCCTGCAGGAGCTGGATGTGAGCAACCTAAGCCTGCAGGCCCTGCCTG 1000

Qy 961 GCGACCTCTCGGGCCTCTTCCCCCGCCTGCGGCTGCTGGCAGCTGCCCCGAACCCCTTCA 1020
 |||
 Db 1001 GCGACCTCTCGGGCCTCTTCCCCCGCCTGCGGCTGCTGGCAGCTGCCCCGAACCCCTTCA 1060

Qy 1021 ACTGCGTGTGCCCCCTGAGCTGGTTTGGCCCCCTGGGTGCGCGAGAGCCACGTCACTGG 1080
 |||
 Db 1061 ACTGCGTGTGCCCCCTGAGCTGGTTTGGCCCCCTGGGTGCGCGAGAGCCACGTCACTGG 1120

Qy 1081 CCAGCCCTGAGGAGACGCGCTGCCACTTCCCGCCCAAGAACGCTGGCCGGCTGCTCCTGG 1140
 |||
 Db 1121 CCAGCCCTGAGGAGACGCGCTGCCACTTCCCGCCCAAGAACGCTGGCCGGCTGCTCCTGG 1180

Qy 1141 AGCTTGACTACGCCGACTTTGGCTGCCCAGCCACCACCACAGCCACAGTGCCACCA 1200
 |||
 Db 1181 AGCTTGACTACGCCGACTTTGGCTGCCCAGCCACCACCACAGCCACAGTGCCACCA 1240

Qy 1201 CGAGGCCCCGTGGTGCGGGAGCCCACAGCCTTGTCTTCTAGCTTGGCTCCTACCTGGCTTA 1260
 |||
 Db 1241 CGAGGCCCCGTGGTGCGGGAGCCCACAGCCTTGTCTTCTAGCTTGGCTCCTACCTGGCTTA 1300

Qy 1261 GCCCCACAGCGCCGGCCACTGAGGCCCCCAGCCCGCCCTCCACTGCCCCACCGACTGTAG 1320
 |||
 Db 1301 GCCCCACAGCGCCGGCCACTGAGGCCCCCAGCCCGCCCTCCACTGCCCCACCGACTGTAG 1360

Qy 1321 GGCCTGTCCCCAGCCCCAGGACTGCCCCACCGTCCACCTGCCTCAATGGGGGCACATGCC 1380
 |||||
 Db 1361 GGCCTGTCCCCAGCCCCAGGACTGCCCCACCGTCCACCTGCCTCAATGGGGGCACATGCC 1420

Qy 1381 ACCTGGGGACACGGCACCACCTGGCGTGCTTGTGCCCCGAAGGCTTCACGGGCCTGTACT 1440
 |||||
 Db 1421 ACCTGGGGACACGGCACCACCTGGCGTGCTTGTGCCCCGAAGGCTTCACGGGCCTGTACT 1480

Qy 1441 GTGAGAGCCAGATGGGGCAGGGGACACGGCCCAGCCCTACACCAGTCACGCCGAGGCCAC 1500
 |||||
 Db 1481 GTGAGAGCCAGATGGGGCAGGGGACACGGCCCAGCCCTACACCAGTCACGCCGAGGCCAC 1540

Qy 1501 CACGGTCCCTGACCCTGGGCATCGAGCCGGTGAGCCCCACCTCCCTGCGCGTGGGGCTGC 1560
 |||||
 Db 1541 CACGGTCCCTGACCCTGGGCATCGAGCCGGTGAGCCCCACCTCCCTGCGCGTGGGGCTGC 1600

Qy 1561 AGCGCTACCTCCAGGGGAGCTCCGTGCAGCTCAGGAGCCTCCGTCTCACCTATCGCAACC 1620
 |||||
 Db 1601 AGCGCTACCTCCAGGGGAGCTCCGTGCAGCTCAGGAGCCTCCGTCTCACCTATCGCAACC 1660

Qy 1621 TATCGGGCCCTGATAAGCGGCTGGTGACGCTGCGACTGCCTGCCTCGCTCGCTGAGTACA 1680
 |||||
 Db 1661 TATCGGGCCCTGATAAGCGGCTGGTGACGCTGCGACTGCCTGCCTCGCTCGCTGAGTACA 1720

Qy 1681 CGGTCAACCAGCTGCGGCCCAACGCCACTTACTCCGTCTGTGTGCATGCCTTTGGGGCCCCG 1740
 |||||
 Db 1721 CGGTCAACCAGCTGCGGCCCAACGCCACTTACTCCGTCTGTGTGCATGCCTTTGGGGCCCCG 1780

Qy 1741 GGCGGGTGCCGGAGGGCGAGGAGGCCTGCGGGGAGGGCCATACACCCCAGCCGTCCACT 1800
 |||||
 Db 1781 GGCGGGTGCCGGAGGGCGAGGAGGCCTGCGGGGAGGGCCATACACCCCAGCCGTCCACT 1840

Qy 1801 CCAACCACGCCCCAGTCACCCAGGCCCCGCGAGGGCAACCTGCCGCTCCTCATTGCGCCCCG 1860
 |||||
 Db 1841 CCAACCACGCCCCAGTCACCCAGGCCCCGCGAGGGCAACCTGCCGCTCCTCATTGCGCCCCG 1900

Qy 1861 CCCTGGCCGCGGTGCTCCTGGCCGCGCTGGCTGCGGTGGGGGCAGCCTACTGTGTGCGGC 1920
 |||||
 Db 1901 CCCTGGCCGCGGTGCTCCTGGCCGCGCTGGCTGCGGTGGGGGCAGCCTACTGTGTGCGGC 1960

Qy 1921 GGGGGCGGGCCATGGCAGCAGCGGCTCAGGACAAAGGGCAGGTGGGGCCAGGGGCTGGGC 1980
 |||||
 Db 1961 GGGGGCGGGCCATGGCAGCAGCGGCTCAGGACAAAGGGCAGGTGGGGCCAGGGGCTGGGC 2020

Qy 1981 CCCTGGAAGTGGAGGGAGTGAAGGTCCCCTTGGAGCCAGGCCCCGAAGGCAACAGAGGGCG 2040
 |||||
 Db 2021 CCCTGGAAGTGGAGGGAGTGAAGGTCCCCTTGGAGCCAGGCCCCGAAGGCAACAGAGGGCG 2080

Qy 2041 GTGGAGAGGCCCTGCCAGCGGGTCTGAGTGTGAGGTGCCACTCATGGGCTTCCCAGGGC 2100
 |||||
 Db 2081 GTGGAGAGGCCCTGCCAGCGGGTCTGAGTGTGAGGTGCCACTCATGGGCTTCCCAGGGC 2140

Qy 2101 CTGGCCTCCAGTCACCCCTCCACGCAAAGCCCTACATCTAAGCCAGAGAGAGACAGGGCA 2160
 |||||
 Db 2141 CTGGCCTCCAGTCACCCCTCCACGCAAAGCCCTACATCTAAGCCAGAGAGAGACAGGGCA 2200

Qy 2161 GCTGGGGCCGGGCTCTCAGCCAGTGAGATGGCCAGCCCCCTCCTGCTGCCACACCACGTA 2220

Db 2201 GCTGGGGCCGGGCTCTCAGCCAGTGAGATGGCCAGCCCCCTCCTGCTGCCACACCACGTA 2260
Qy 2221 AGTTCTCAGTCCCAACCTCGGGGATGTGTGCAGACAGGGCTGTGTGACCACAGCTGGGCC 2280
Db 2261 AGTTCTCAGTCCCAACCTCGGGGATGTGTGCAGACAGGGCTGTGTGACCACAGCTGGGCC 2320
Qy 2281 CTGTTCCCTCTGGACCTCGGTCTCCTCATCTGTGAGATGCTGTGGCCCAGCTGACGAGCC 2340
Db 2321 CTGTTCCCTCTGGACCTCGGTCTCCTCATCTGTGAGATGCTGTGGCCCAGCTGACGAGCC 2380
Qy 2341 CTAACGTCCCCAGAACCGAGTGCCTATGAGGACAGTGTCCGCCCTGCCCTCCGCAACGTG 2400
Db 2381 CTAACGTCCCCAGAACCGAGTGCCTATGAGGACAGTGTCCGCCCTGCCCTCCGCAACGTG 2440
Qy 2401 CAGTCCCTGGGCACGGCGGGCCCTGCCATGTGCTGGTAACGCATGCCTGGGTCCTGCTGG 2460
Db 2441 CAGTCCCTGGGCACGGCGGGCCCTGCCATGTGCTGGTAACGCATGCCTGGGTCCTGCTGG 2500
Qy 2461 GCTCTCCCACTCCAGGCGGACCCTGGGGGCCAGTGAAGGAAGCTCCCGGAAAGAGCAGAG 2520
Db 2501 GCTCTCCCACTCCAGGCGGACCCTGGGGGCCAGTGAAGGAAGCTCCCGGAAAGAGCAGAG 2560
Qy 2521 GGAGAGCGGGTAGGCGGCTGTGTGACTCTAGTCTTGGCCCCAGGAAGCGAAGGAACAAAA 2580
Db 2561 GGAGAGCGGGTAGGCGGCTGTGTGACTCTAGTCTTGGCCCCAGGAAGCGAAGGAACAAAA 2620
Qy 2581 GAAACTGGAAAGGAAGATGCTTTAGGAACATGTTTTGCTTTTTTAAA--ATATATATATT 2638
Db 2621 GAAACTGGAAAGGAAGATGCTTTAGGAACATGTTTTGCTTTTTTAAAATATATATATATT 2680
Qy 2639 TATAAGAGATCCTTTCCCATTTATTCTGGGAAGATGTTTTTCAAACCTCAGAGACAAGGAC 2698
Db 2681 TATAAGAGATCCTTTCCCATTTATTCTGGGAAGATGTTTTTCAAACCTCAGAGACAAGGAC 2740
Qy 2699 TTTGGTTTTTTGTAAGACAAACGATGATATGAAGGCCTTTTGTAAAGAAAAATAAAAGATG 2758
Db 2741 TTTGGTTTTTTGTAAGACAAACGATGATATGAAGGCCTTTTGTAAAGAAAAATAAAAGATG 2800
Qy 2759 AAGTGTGAAA 2768
Db 2801 AAGTGTGAAA 2810